Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19486191 | 0.86 | SYK (0.34) | SYK | |
| SCHEMBL21550321 | 0.84 | SYK (0.33) | SYK | |
| SCHEMBL6950382 | 0.84 | SYK (0.33) | SYK | |
| SCHEMBL1672816 | 0.84 | SYK (0.33) | SYK | |
| SCHEMBL12690059 | 0.81 | SYK (0.32) | SYK | |
| SCHEMBL12690045 | 0.81 | SYK (0.32) | SYK | |
| SCHEMBL2947840 | 0.81 | SYK (0.34) | SYK | |
| SCHEMBL19045190 | 0.77 | PDE4A (0.33) | SYK | |
| SCHEMBL28830304 | 0.76 | FEN1 (0.32) | SYK | |
| SCHEMBL28908986 | 0.76 | FEN1 (0.32) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491045-B1 | 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | EP | disclosed |
| US-8822508-B2 | 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives | UCB PHARMA, S.A. (BE) | 2014-09-02 | — | — | US | disclosed |
| US-20120245208-A1 | 2-Oxo-1-Pyrrolidinyl Imidazothiadiazole Derivatives | UCB PHARMA, S.A. (BE) | 2012-09-27 | — | — | US | disclosed |
| EP-2491045-A1 | 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB Pharma S.A. (BE) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011047860-A1 | 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB PHARMA, S.A. (BE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245208-A1 | 2-Oxo-1-Pyrrolidinyl Imidazothiadiazole Derivatives | CYP3A4, CYP3A43, CYP3A7 | SYK 2758/4885CGAS 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.